Want to see ACAD full AI Analyst Report?

ACADIA Pharmaceuticals (ACAD) Price & Analysis

2,438 Followers

ACAD Stock Chart & Stats

$22.17

-$0.09(-0.52%)

At close: Jan 08 4:00 PM EST

$22.17

-$0.09(-0.52%)

Day’s Range― - ―

52-Week Range$19.69 - $28.35

Previous CloseN/A

Volume443.16K

Average Volume (3M)1.48M

Market Cap

$4.45B

Enterprise Value$3.47B

Total Cash (Recent Filing)$851.46M

Total Debt (Recent Filing)$50.79M

Price to Earnings (P/E)11.6

Beta1.06

Next Earnings

Aug 11, 2026

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.23

Shares Outstanding171,235,870

10 Day Avg. Volume1,274,430

30 Day Avg. Volume1,479,599

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)3.69

Price to Sales (P/S)4.22

P/FCF Ratio43.02

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue3.17

Enterprise Value/Gross Profit3.46

Enterprise Value/Ebitda27.32

Forecast

1Y Price Target

$32.43

Price Target Upside46.27% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

EPS Forecast (FY)0.39

Revenue Forecast (FY)$1.24B

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet And Cash RunwayA strong cash balance ($851M) and very low leverage provide durable financial flexibility to fund commercial expansion, near‑term clinical readouts, and R&D without dependence on markets. This reduces refinancing risk and supports execution over the next 2–6 months.

Durable Product Revenue Growth And Commercial MomentumConsistent top‑line growth across core products, plus physician referral gains and expanded sales force, indicates durable underlying demand. Expanded field coverage and DAYBUE STIX adoption support sustainable revenue scaling through H2 and into 2026–2028 planning horizons.

Profitability Turnaround With High Gross MarginsThe move from multi‑year losses to solid net profitability and persistently high gross margins underpins durable earnings power. High product gross margins give pricing and reinvestment flexibility, enabling continued R&D and commercial investment even if operating margins fluctuate.

Bears Say

Material Gross‑to‑net Revenue ReductionsVery high gross‑to‑net deductions materially reduce net realizable revenues and weaken revenue durability versus list sales. Over time, elevated rebates and discounts compress cash conversion and margin sustainability, increasing sensitivity to payer dynamics and pricing pressure.

Weak Operating Cash Flow Coverage And Choppy Free Cash FlowOperating cash flow trailing net income and uneven free cash flow introduce execution risk: funding commercial expansion and multiple Phase II/III readouts may rely on cash reserves. This mismatch increases the importance of disciplined expense control to sustain investments without external financing.

Regulatory Uncertainty For Trofinetide In EuropeOngoing reexamination in Europe creates a structural commercialization risk for a late‑stage asset. Delays or adverse outcomes would limit market access and revenue opportunity in a material geography and could require additional trials or regulatory engagement, affecting medium‑term pipeline value.

ACADIA Pharmaceuticals News

Acadia Pharmaceuticals price target raised to $30 from $29 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $29 and...

4d ago

ACAD

EU’s CHMP reverses course on Acadia’s trofinetide, says H.C. Wainwright

The CHMP last week issued a positive re-examination opinion recommending EU approval for Acadia’s DAYBU, or trofinetide, after...

5d ago

ACAD

Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank

Deutsche Bank analyst David Hoang raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32...

5d ago

ACAD

Acadia Pharmaceuticals price target raised to $36 from $32 at Canaccord

Canaccord analyst Sumant Kulkarni raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $32 and...

5d ago

ACAD

Citi adds ‘upside 90-day catalyst watch’ on Acadia Pharmaceuticals

Citi added an “upside 90-day catalyst watch” on Acadia Pharmaceuticals (ACAD) while keeping a Buy rating on the...

5d ago

ACAD

Acadia Pharmaceuticals price target raised to $35 from $32 at Citi

Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $32 and keeps a Buy...

5d ago

ACAD

Acadia Pharmaceuticals rises 13.4%

Acadia Pharmaceuticals (ACAD) is up 13.4%, or $3.17 to $26.89. Published first on TheFly – the ultimate source...

8d ago

ACAD

Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO

The major averages were fractionally higher near noon despite another wave of weakness hitting large-cap technology and semiconductor...

8d ago

Acadia Pharmaceuticals Stock (ACAD) Jumps on a Positive CHMP Review

Acadia Pharmaceuticals stock was up on Friday alongside a positive review of its Rett syndrome treatment. ...

8d ago

ACAD

Acadia Pharmaceuticals rises 9.9%

Acadia Pharmaceuticals (ACAD) is up 9.9%, or $2.35 to $26.07. Published first on TheFly – the ultimate source...

8d ago

ACAD

Acadia Pharmaceuticals: Daybu recommended for approval in EU by CHMP

Acadia Pharmaceuticals (ACAD) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency...

8d ago

ACAD

Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals, with...

7d ago

ACAD

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan

ACADIA Pharmaceuticals ( ($ACAD) ) has issued an announcement. Acadia Pharmaceuticals Inc. held its 2026 Annual Meeting of...

1M ago

ACAD

ACADIA Pharmaceuticals Signals Confident Path After Q1 Call

ACADIA Pharmaceuticals Inc. (($ACAD)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

ACAD

ACAD FAQ

What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?

ACADIA Pharmaceuticals Inc. lowest stock price was $19.69 and its highest was $28.35 in the past 12 months.

What is ACADIA Pharmaceuticals Inc.’s market cap?

ACADIA Pharmaceuticals Inc.’s market cap is $4.45B.

When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?

ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.

How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?

ACADIA Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.

Is ACADIA Pharmaceuticals Inc. overvalued?

According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ACADIA Pharmaceuticals Inc. pay dividends?

ACADIA Pharmaceuticals Inc. does not currently pay dividends.

What is ACADIA Pharmaceuticals Inc.’s EPS estimate?

ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.06.

How many shares outstanding does ACADIA Pharmaceuticals Inc. have?

ACADIA Pharmaceuticals Inc. has 171,235,870 shares outstanding.

What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?

ACADIA Pharmaceuticals Inc. reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went up 5.028%.

Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in ACAD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ACADIA Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

35.65%

Trailing 12-Months

Asset Growth

41.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

ACADIA Pharmaceuticals (ACAD) Earnings & Revenues

Historic Earnings Reports

ACAD Company Deck

ACAD Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented a predominantly positive commercial and pipeline picture: solid Q1 revenue growth (+11% adjusted), robust DAYBUE momentum (+20% YoY) and encouraging early uptake of the DAYBUE STIX formulation, continued demand and referral gains for NUPLAZID, a strong cash position ($851M) and major near‑term clinical catalysts (remlifanserin Phase II readout and trofinetide Japan Phase III). Headwinds include a temporary refill timing disruption that impacted Q1 NUPLAZID revenue timing, a sizable near‑term increase in SG&A (+35.3% YoY) to fund commercial expansion, ongoing regulatory uncertainty in Europe for trofinetide, and an R&D leadership transition. On balance, the positives (top‑line growth, product launches, reaffirmed guidance, pipeline catalysts and healthy cash) outweigh the challenges, which management describes largely as temporary or strategic investments.View all ACAD earnings summaries

ACAD Stock 12 Month Forecast

Average Price Target

$32.43

▲(46.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","39":"$39","24.75":"$24.8","29.5":"$29.5","34.25":"$34.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,24.75,29.5,34.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.2,26.184615384615384,27.16923076923077,28.153846153846153,29.138461538461538,30.123076923076923,31.107692307692307,32.09230769230769,33.07692307692308,34.06153846153846,35.04615384615384,36.03076923076923,37.01538461538462,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.2,25.756043956043957,26.31208791208791,26.86813186813187,27.424175824175826,27.98021978021978,28.536263736263738,29.092307692307692,29.64835164835165,30.204395604395607,30.76043956043956,31.31648351648352,31.872527472527473,{"y":32.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.2,25.03076923076923,24.861538461538462,24.692307692307693,24.52307692307692,24.353846153846153,24.184615384615384,24.015384615384615,23.846153846153847,23.676923076923078,23.507692307692306,23.338461538461537,23.16923076923077,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >